BioNxt Solutions (XCNQ:BNXT) Debt-to-Equity : -0.93 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is BioNxt Solutions Debt-to-Equity?

BioNxt Solutions's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$4.89 Mil. BioNxt Solutions's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.00 Mil. BioNxt Solutions's Total Stockholders Equity for the quarter that ended in Dec. 2023 was C$-5.28 Mil. BioNxt Solutions's debt to equity for the quarter that ended in Dec. 2023 was -0.93.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for BioNxt Solutions's Debt-to-Equity or its related term are showing as below:

XCNQ:BNXT' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.06 Med: 0.16 Max: 3.27
Current: -0.93

During the past 6 years, the highest Debt-to-Equity Ratio of BioNxt Solutions was 3.27. The lowest was -1.06. And the median was 0.16.

XCNQ:BNXT's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.29 vs XCNQ:BNXT: -0.93

BioNxt Solutions Debt-to-Equity Historical Data

The historical data trend for BioNxt Solutions's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNxt Solutions Debt-to-Equity Chart

BioNxt Solutions Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.22

0.83

3.27

-1.06

-0.93

BioNxt Solutions Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															1.67	-1.06	-1.97	-1.21	-0.93

Competitive Comparison of BioNxt Solutions's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, BioNxt Solutions's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioNxt Solutions's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioNxt Solutions's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where BioNxt Solutions's Debt-to-Equity falls into.

BioNxt Solutions Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

BioNxt Solutions's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.894	+	0)	/	-5.283
	=	-0.93

BioNxt Solutions's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.894	+	0)	/	-5.283
	=	-0.93

BioNxt Solutions (XCNQ:BNXT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

BioNxt Solutions Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of BioNxt Solutions's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

BioNxt Solutions (XCNQ:BNXT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioNxt Solutions Inc (XCNQ:BNXT) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

BNXTF:USA BXT:Germany

Address

1820 Fir Street, Suite 270, Vancouver, BC, CAN, V6J 3B1

Website

https://www.bionxt.com

BioNxt Solutions Inc is a cannabis company engaged in developing analytical testing, processing, and formulation capability in Canada. It is also engaged in research, cultivation, extraction, import, distribution, and manufacturing in Germany. The products of the company include Drug Delivery, Point-of-Care Diagnostics, and Psychedelics.

BioNxt Solutions (XCNQ:BNXT) Headlines

No Headlines